Filing Flows › Comparisons › IRD vs SPRB
Opus Genetics vs Spruce Biosciences: IRD and SPRB compared
Opus Genetics is the larger company: $755K of revenue in its latest quarter (Q2 2026) against $697K for Spruce Biosciences (Q4 2024). Opus Genetics is growing faster (-74% against -76% a year earlier).
Where the money goes: IRD and SPRB
Opus Genetics (IRD) · Q2 2026
Opus Genetics, Q2 2026: revenue $755K (-74% year over year), net loss $8.1M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Spruce Biosciences (SPRB) · Q4 2024
Spruce Biosciences, Q4 2024: revenue $697K (-76% year over year), net loss $23.6M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
| Opus Genetics (IRD) | Spruce Biosciences (SPRB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2024 |
| Revenue | $755K | $697K |
| Revenue growth, Y/Y | -74% | -76% |
| Operating margin | n/m | n/m |
| Net earnings | −$8.1M | −$23.6M |
| Operating cash flow | −$11.9M | −$20.7M |
Questions
Which is bigger, Opus Genetics or Spruce Biosciences?
Opus Genetics is the larger company: $755K of revenue in its latest quarter (Q2 2026) against $697K for Spruce Biosciences (Q4 2024).
Is Opus Genetics or Spruce Biosciences growing faster?
Opus Genetics is growing faster (-74% against -76% a year earlier).
More: Opus Genetics earnings · how Opus Genetics makes money · Spruce Biosciences earnings · how Spruce Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-K filed Apr 15, 2025). Fiscal quarters can end on different dates. Not investment advice.